Pharmamarketeer
onderzoek

Oncolytics Biotech announces publication of positive results for pelareorep in abstract for ESMO 2018 Congress

15 oktober 2018
Pharma Biz

Oncolytics Biotech Inc, currently developing pelareorep, an intravenously delivered immuno-oncolytic virus turning cold tumours hot, announced publication of an abstract on pelareorep (formerly known as Reolysin) for the European Society for Medical Oncology (ESMO) 2018 Congress, taking place October 19-23 in Munich.

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)